PharmacyCodes



Bextra en es it fr

Categoria

Bextra Nombres de marca, Bextra Analogos

Bextra Marca los nombres de mezcla

  • No information avaliable

    • Bextra Formula quimica

    C16H14N2O3S

    Bextra RX enlace

    http://www.rxlist.com/cgi/generic/bextra.htm

    Bextra FDA hoja

    Bextra FDA

    Bextra MSDS (hoja de seguridad de materiales)

    Bextra Sintesis de referencia

    No hay información disponible

    Bextra Peso molecular

    314.36 g/mol

    Bextra Punto de fusion

    No information avaliable

    Bextra H2O Solubilidad

    No hay información disponible

    Bextra Estado

    Solid

    Bextra LogP

    3.003

    Bextra Formas de dosificacion

    Tableta

    Bextra Indicacion

    Para el tratamiento de la artrosis y dismenorrea

    Bextra Farmacologia

    Valdecoxib, un ciclooxigenasa-2 (COX-2) inhibidores, se clasifica como antiinflamatorios no esteroideos (AINE). Valdecoxib se utiliza para sus actividades anti-inflamatorias, analgésicas y antipiréticas en el manejo de la osteoartritis (OA) y para el tratamiento de la dismenorrea o dolor agudo. A diferencia de celecoxib, valdecoxib carece de una cadena sulfonamida y no requiere de enzimas del citocromo P450 para el metabolismo.

    Bextra Absorcion

    No hay información disponible

    Bextra Toxicidad

    No hay información disponible

    Bextra Informacion de Pacientes

    BEXTRA can cause GI discomfort and, rarely, more serious GI side effects, which may result in hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up Effects ó Risk of GI Ulceration, Bleeding, and Perforation).

    Patients should report to their physicians, signs or symptoms of gastrointestinal ulceration or bleeding, skin rash, weight gain, or edema.

    Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and flu-like symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical attention.

    Patients should also be instructed to seek immediate emergency help in the case of an anaphylactoid reaction.

    In late pregnancy, BEXTRA should be avoided because it may cause premature closure of the ductus arteriosus.

    Bextra Organismos afectados

    Humanos y otros mamíferos